Loading...
Market
Will any new scientific study in 2024 find a link between ranitidine and cancer?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Publications in peer-reviewed scientific journals
Story
GSK Wins Chicago Court Case Over Zantac Cancer Claims on Monday
Aug 5, 2024, 09:57 PM
GlaxoSmithKline (GSK) has secured a victory in an Illinois state court as a jury in Chicago found the company not liable for a woman's colorectal cancer on Monday. The case centered around claims that the now-discontinued heartburn drug Zantac caused the illness. This verdict aligns with the scientific consensus that there is no consistent or reliable evidence linking ranitidine, the active ingredient in Zantac, to an increased risk of any cancer. This marks the second consecutive trial win for GSK amidst hundreds of similar lawsuits in Illinois.
View original story
Similar markets
No evidence found • 25%
Some evidence found • 25%
Significant evidence found • 25%
Inconclusive • 25%
Confirms current findings • 25%
Shows no significant change • 25%
Shows increased risk • 25%
Shows reduced risk but less than current findings • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
GSK • 25%
Sanofi • 25%
Pfizer • 25%
Other • 25%
Yes • 50%
No • 50%
Less than 5 • 25%
5 to 10 • 25%
10 to 15 • 25%
More than 15 • 25%
